Jennifer C. Burstein
Independent DirectorMs. Jennifer C. Burstein, M.B.A. CPA, serves as Independent Director of Stoke Therapeutics, Inc. since June 14, 2019. She joined the Stoke Therapeutics, Inc. on June 14, 2019. She has been Treasurer at Treeline Biosciences, Inc. Ms. Burstein served as Senior Vice President of Finance of Loxo Oncology, Inc since January 2018 until February 2019 and served as its and Principal Financial Officer since May 2015. Since March 1, 2021, Ms. Burstein has served as Senior Vice President – Finance Operations at Treeline Biosciences, Inc., a biotechnology company. She served as Vice President of Finance of Loxo Oncology, Inc. since May 1, 2015. Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc. from July 2010 to April 2015. Ms. Burstein served as an Executive Director and Director of Finance since joining Acorda in 2006. Ms. Burstein was responsible for all finance related activities including SEC filings, financings, SOX implementation and monitoring, financial closes, collaboration accounting, budgeting and Ampyra launch-related accounting issues. Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company. Ms. Burstein held several positions of increasing responsibility for Eyetech Pharmaceuticals including Senior Director of Accounting. She has a CPA license in New York. Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo.
Positions
- Company NameStoke Therapeutics, Inc.Stock CodeSTOKPositionIndependent Director
